GlassScriptPhysician profile
Aman U Khan
NPI 1235236258
$5,187.48
in general payments reported to CMS, 2019-2025
41 companies · $1,124 in 2025
The $1,124 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $508 · 2020: $167 · 2021: $627 · 2022: $986 · 2023: $1,037 · 2024: $739 · 2025: $1,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,705 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,704.85 |
| Education | $194.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $755.39 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Jazz Pharmaceuticals INC. | $446.79 | 2019-2025 | |
| Glaxosmithkline, LLC. | $426.13 | 2019-2025 | Trelegy Ellipta, Nucala |
| Genentech USA, INC. | $348.11 | 2019-2025 | Xolair |
| Actelion Pharmaceuticals US, INC. | $345.68 | 2019-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.24 | 2019-2025 | Spiriva Respimat, Stiolto Respimat, Ofev |
| Insmed, INC. | $303.47 | 2021-2025 | Arikayce |
| Mylan Specialty L.P. | $300.50 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $235.41 | 2022-2025 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $169.60 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $163.60 | 2019-2023 | |
| Zoll Respicardia, INC. | $155.28 | 2025 | Remede System |
| Janssen Pharmaceuticals, INC | $146.07 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $113.34 | 2019-2023 | Camzyos |
| Astellas Pharma US INC | $92.36 | 2025 | Cresemba |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $75.84 | 2025 | Yupelri |
| Philips North America LLC | $71.98 | 2019-2024 | (7999) Src Undivided |
| Baxter Healthcare | $70.03 | 2023-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Vest System Model 205 Acute Care |
| Genzyme Corporation | $64.56 | 2022-2024 | |
| Axsome Therapeutics, INC. | $45.20 | 2025 | Sunosi |
| Inogen, INC. | $42.16 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Pulmonx Corporation | $40.56 | 2022-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Abbvie INC. | $39.78 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $39.14 | 2019 | |
| Electromed, INC. | $35.00 | 2021-2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $34.83 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $28.69 | 2024 | Dupixent |
| Pfizer INC. | $26.42 | 2019 | |
| Inspire Medical Systems, INC. | $25.40 | 2024 | Inspire |
| Amgen INC. | $24.65 | 2023 | Tezspire |
| Bard Access Systems, INC. | $21.82 | 2019 | |
| Merck Sharp & Dohme LLC | $21.26 | 2023 | |
| Ani Pharmaceuticals, INC. | $21.06 | 2024 | Purified Cortrophin Gel |
| Bayer Healthcare Pharmaceuticals INC. | $19.73 | 2023 | |
| Nabriva Therapeutics, Plc | $19.15 | 2021 | |
| Azurity Pharmaceuticals, INC. | $18.82 | 2024 | Horizant |
| Circassia INC. | $17.36 | 2019 | |
| Verona Pharma, INC. | $14.83 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $14.62 | 2019 | |
| Horizon Therapeutics Plc | $13.63 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.